MEIR J STAMPFER, M.D.
Medical Practice at Longwood Ave, Boston, MA
License number
Massachusetts 45522
Category
Medical Practice
Type
Public Health & General Preventive Medicine
Address
Address
2
181 Longwood Ave, Boston, MA 02445
50 Sargent Crossway, Brookline, MA 02445
50 Sargent Crossway, Brookline, MA 02445
Phone
(617) 525-2749
Personal information
See more information about MEIR J STAMPFER at radaris.comName
Address
Phone
50 Sargent Crossway, Brookline, MA 02445
50 Sargent Beechwood, Brookline, MA 02445
50 Sargent Crossway, Brookline, MA 02445
50 Sargent Rd, Brookline, MA 02445
Professional information
Dr. Meir J Stampfer, Boston MA - MD (Doctor of Medicine)
Specialties:
Public Health & General Preventive Medicine, Preventive Medicine
Address:
181 Longwood Ave, Boston 02115
(617) 525-2749 (Phone)
(617) 525-2749 (Phone)
Languages:
English
Education:
Medical School
New York University
Graduated: 1977
Maimonides Med Center
Mt Sinai School Med Comm Med
New York University
Graduated: 1977
Maimonides Med Center
Mt Sinai School Med Comm Med
Meir J Stampfer, Boston MA
Specialties:
Preventive Medicine, Public Health & General Preventive Medicine, Public Health
Work:
Channing Laboratory
181 Longwood Ave, Boston, MA 02115
181 Longwood Ave, Boston, MA 02115
Education:
New York University (1977)
Circulating Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3 And Prostate Cancer Risk
US Patent:
6645770, Nov 11, 2003
Filed:
Mar 14, 2001
Appl. No.:
09/808459
Inventors:
Michael N. Pollak - Montreal, CA
Meir J. Stampfer - Brookline MA
Edward Giovannucci - Wakefield MA
Meir J. Stampfer - Brookline MA
Edward Giovannucci - Wakefield MA
Assignee:
The Brigham Womens Hospital, Inc. - Boston MA
Lady Davis Institute - Montreal
Lady Davis Institute - Montreal
International Classification:
G01N 3348
US Classification:
436 64, 436 63, 435 4, 435 71, 530350, 530399
Abstract:
Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
Circulating Insulin-Like Growth Factor-I And Prostate Cancer Risk
US Patent:
6410335, Jun 25, 2002
Filed:
Jan 21, 1999
Appl. No.:
09/234651
Inventors:
Michael N. Pollak - Montreal, CA
Meir J. Stampfer - Brookline MA
Edward Giovannucci - Wakefield MA
Meir J. Stampfer - Brookline MA
Edward Giovannucci - Wakefield MA
Assignee:
The Brigham and Womans Hospital, Inc. - Boston MA
Sir Mortimer B. Davis - Jewish General Hospital Foundation - Montreal
Sir Mortimer B. Davis - Jewish General Hospital Foundation - Montreal
International Classification:
G01N 3348
US Classification:
436 64, 436 63, 435 4
Abstract:
Methods of predicting a propensity to developing prostate cancer are presented. The consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA staus (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a porrer overall prognosis.
Circulating Insulin-Like Growth Factor-I And Prostate Cancer Risk
US Patent:
2003004, Mar 6, 2003
Filed:
Dec 18, 2001
Appl. No.:
10/025350
Inventors:
Michael Pollak - Montreal, CA
Meir Stampfer - Brookline MA, US
Edward Giovannucci - Wakefield MA, US
Meir Stampfer - Brookline MA, US
Edward Giovannucci - Wakefield MA, US
Assignee:
Lady Davis Institute - Montreal
International Classification:
G01N033/574, G06F019/00
US Classification:
435/007230, 702/019000
Abstract:
Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.